A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma

References

• Ludwig H, Novis Durie S, Meckl A, et al. Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist. 2020;25(9):e1406–e13. doi: 10.1634/theoncologist.2020-0141.
   PubMed Web of Science ®Google Scholar
• Cancer Research UK. Multiple myeloma; 2020. Available from: https://www.cancerresearchuk.org/about-cancer/myeloma/about.
   Google Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5(2):e528.
   PubMed Web of Science ®Google Scholar
• Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers. 2020;12(2):265. doi: 10.3390/cancers12020265.
   PubMed Web of Science ®Google Scholar
• Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1–7. doi: 10.1016/j.clml.2019.09.621.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Multiple myeloma version 3.2023. [cited 2022 Nov 23]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf.
   Google Scholar
• Padala SA, Barsouk A, Barsouk A, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci. 2021;9(1):1–14. doi: 10.3390/medsci9010003.
   Google Scholar
• Cornell RF, Kassim AA. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant. 2016;51(4):479–491. doi: 10.1038/bmt.2015.307.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79(7):867–874. doi: 10.4065/79.7.867.
   PubMed Web of Science ®Google Scholar
• Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275. doi: 10.1038/s41375-019-0435-7.
   PubMed Web of Science ®Google Scholar
• Bal S, Malek E, Kansagra A, et al. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia. 2022;36(3):877–880. doi: 10.1038/s41375-021-01471-3.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36(5):1371–1376. doi: 10.1038/s41375-022-01531-2.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Summary of product characteristics: nexpovio. Amsterdam. [cited 2021 May 27]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/nexpovio.
   Google Scholar
• European Medicines Agency. Summary of Product Characteristics: Abecma. Amsterdam. [cited 2021 August 25]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/abecma.
   Google Scholar
• Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in multiple myeloma-a promising key to therapy. J Clin Med. 2021;10(18):1–17. doi: 10.3390/jcm10184088.
   Web of Science ®Google Scholar
• Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–738. doi: 10.1056/NEJMoa1903455.
   PubMed Web of Science ®Google Scholar
• Liu A. J&J shelves Carvykti’s UK launch amid manufacturing shortfalls. FiercePharma. 2023.
   Google Scholar
• AerzteZeitung. Janssen führt neues Blutkrebsmittel nicht in Deutschland ein. AerzteZeitung.de. 2022.
   Google Scholar
• Food and Drug Administration. FDA grants accelerated approval to elranatamab-BCMM for multiple myeloma. 2023. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma.
   Google Scholar
• Kociszewska K, Bednarczyk M, Grosicki S. Elranatamab: a new promising BispAb in multiple myeloma treatment. Expert Rev Anticancer Ther. 2023;23(8):775–782. doi: 10.1080/14737140.2023.2236303.
   PubMed Web of Science ®Google Scholar
• Landgren O, Nadeem O. Bispecific monoclonal antibodies in multiple myeloma: data from ASH 2022: a podcast. Adv Ther. 2023;40(8):3291–3303. doi: 10.1007/s12325-023-02551-9.
   PubMed Web of Science ®Google Scholar
• Tanenbaum B, Miett T, Patel SA. The emerging therapeutic landscape of relapsed/refractory multiple myeloma. Ann Hematol. 2023;102(1):1–11. doi: 10.1007/s00277-022-05058-5.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259–2267. doi: 10.1038/s41591-023-02528-9.
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200–211. doi: 10.1177/0272989X17725740.
   PubMed Web of Science ®Google Scholar
• Remiro-Azócar A, Heath A, Baio G. Methods for population adjustment with limited access to individual patient data: a review and simulation study. Res Synth Methods. 2021;12(6):750–775. doi: 10.1002/jrsm.1511.
   PubMed Web of Science ®Google Scholar
• Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics. 2015;33(6):537–549. doi: 10.1007/s40273-015-0271-1.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947. doi: 10.1016/j.jval.2012.05.004.
   PubMed Web of Science ®Google Scholar
• Phillippo D, Ades T, Dias S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. University of Sheffield, NICE Decision Support Unit; 2016. p. 82.
   Google Scholar
• Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. doi: 10.1186/1471-2288-12-9.
   PubMed Web of Science ®Google Scholar
• Moreau P, van de Donk N, Delforge M, et al. Comparative efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective LocoMMotion study in patients with triple-class-exposed relapsed and/or refractory multiple myeloma. Adv Ther. 2023;40(5):2412–2425. doi: 10.1007/s12325-023-02480-7.
   PubMed Web of Science ®Google Scholar
• Shah N, Mojebi A, Ayers D, et al. Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma. J Comp Eff Res. 2022;11(10):737–749. doi: 10.2217/cer-2022-0045.
   PubMed Web of Science ®Google Scholar
• Jakobsen JC, Gluud C, Wetterslev J, et al. When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(1):162. doi: 10.1186/s12874-017-0442-1.
   PubMed Web of Science ®Google Scholar
• Olivier T, Prasad V. The approval and withdrawal of melphalan flufenamide (melflufen): implications for the state of the FDA. Transl Oncol. 2022;18:101374. doi: 10.1016/j.tranon.2022.101374.
   PubMed Web of Science ®Google Scholar
• Ray U, Orlowski RZ. Antibody-drug conjugates for multiple myeloma: just the beginning, or the beginning of the end? Pharmaceuticals. 2023;16(4):590. doi: 10.3390/ph16040590.
   Web of Science ®Google Scholar
• Einsele H, Moreau P, Stefano VD, et al. Subgroup analyses in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study. J Clin Oncol. 2022;40(16_suppl):8031–8031. doi: 10.1200/JCO.2022.40.16_suppl.8031.
   Web of Science ®Google Scholar
• Zanwar S, Ho M, Lin Y, et al. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol. 2023;98(10):1540–1549. doi: 10.1002/ajh.27023.
   PubMed Web of Science ®Google Scholar